Phase 3 Readout
VKTX: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735
August 1, 2027 · vk2735. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 1, 2027
- Company
- Viking Therapeutics, Inc. (VKTX)
- Drug
- vk2735
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735
- Drug
- vk2735
- Indication
- Weight Loss